SER-A-GEN

Pre-Launch

hydralazine hydrochloride; hydrochlorothiazide; reserpine

ANDAORALTABLET

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

SER-A-GEN (hydralazine hydrochloride; hydrochlorothiazide; reserpine) by Sanofi is clinical pharmacology although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Approved for hypertension.

Drug data last refreshed 1mo ago

Mechanism of Action

CLINICAL PHARMACOLOGY Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle.…

Indications (1)

Worked on SER-A-GEN at Sanofi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.